Biotech & Health Tech
Servier's $1.5B bet on Edgewise drug fails five months in
The muscular dystrophy drug that Servier bought for $1.55 billion upfront has already failed its pivotal trial. The drug, called sevasemten, failed the primary and secondary endpoints in the GRAND CANYON pivotal ...
The muscular dystrophy drug that Servier bought for $1.55 billion upfront has already failed its pivotal trial. The drug, called sevasemten, failed the primary and secondary endpoints in the GRAND CANYON pivotal ...
This is a summary of the story. Read the full article at Endpoints News (Biopharma) ↗